Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label attachment file name title
tabling member	label

Search

92003

registered interest
date	26/09/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prescription Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what the cost-per-quality adjusted life year threshold used by the National Institute for Health and Care Excellence and its predecessor bodies to determine the cost-effectiveness of medicines has been in each year since 1999; and what that threshold has been in each year in real terms (a) using the gross domestic product deflator, (b) adjusting for health pay and price inflation and (c) adjusting for the health component of the consumer price index.
tabling member constituency	Bromley and Chislehurst
tabling member printed	Robert Neill
uin	209346
answer	answer is ministerial correction date of answer 16/10/2014 answer text <p>The National Institute for Health and Care Excellence (NICE) does not operate a fixed cost per Quality Adjusted Life Year (QALY) in the development of its technology appraisal guidance. NICE’s <em>Guide to the Methods of Technology Appraisal </em>explains that, for most technology appraisals, it uses a cost per QALY range of £20,000 to £30,000 in its decision-making that enables other factors to be taken into account. This range has remained unchanged since NICE was established in 1999.</p><p> </p><p> </p><p> </p><p>NICE’s technology appraisal methods guide contains further information on the way in which NICE takes the cost per QALY into account in the development of its guidance and is available at:</p><p> </p><p> </p><p> </p><p>www.nice.org.uk/article/pmg9/</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 16/10/2014 16:15:41 answering member 4020 label Biography information for George Freeman
tabling member	1601 label Biography information for Sir Robert Neill

90328

registered interest
date	02/09/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prescription Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, pursuant to the Answer to the hon. Member for Eddisbury of 8 July 2014, Official Report, column 237W, on medical treatments, which appraisals conducted by the National Institute for Health and Care Excellence in the last four years resulted in a recommendation to use a medicine on the NHS and specified criteria for starting and stopping treatment with that medicine; which starting and stopping criteria were applied in each case; for what conditions each such treatment was recommended in each case; what the estimated eligible patient population was for each recommended treatment; and if he will make a statement.
tabling member constituency	Salisbury
tabling member printed	John Glen
uin	207916
answer	answer is ministerial correction date of answer 09/09/2014 answer text <p> </p><p>Information about technology appraisals where the National Institute for Health and Care Excellence (NICE) has included criteria for starting and stopping treatment with the medicine appraised can be found within each published technology appraisal on NICE’s website at:</p><p> </p><p> </p><p> </p><p>www.nice.org.uk</p><p> </p><p> </p><p> </p><p>NICE has advised that collating the information requested would incur disproportionate cost.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 09/09/2014 12:52:59 answering member 4020 label Biography information for George Freeman attachment 1 file name PQ207916 - Hansard Extract.docx title Hansard Extract
tabling member	4051 label Biography information for John Glen

90152

registered interest
date	01/09/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prescription Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what recent discussions he has had with his counterpart in the Northern Ireland Executive on ensuring availability of drugs to treat cancer and MS in all parts of the UK.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	207704
answer	answer is ministerial correction date of answer 08/09/2014 answer text <p>We have had no such discussions.</p><p> </p><p>As the hon. Member will be aware, health is devolved in Northern Ireland and is the responsibility of the Department of Health, Social Services and Public Safety in the Northern Ireland Executive.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 08/09/2014 16:22:16 answering member 4020 label Biography information for George Freeman
tabling member	4131 label Biography information for Jim Shannon

89681

registered interest
date	29/08/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prescription Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what his policy is on making it easier for licensed medication drugs to be used for off-patent treatments.
tabling member constituency	Birmingham, Hall Green
tabling member printed	Mr Roger Godsiff
uin	207483
answer	answer is ministerial correction date of answer 03/09/2014 answer text <p> </p><p>Prescribers should always consider using a licensed medicine within the terms of its licenses as the first option. Where this approach does not meet the clinical needs of a patient, clinicians can prescribe a licensed medicine outside the terms of its license. Information to support clinical decisions on the use of medicines outside their licensed indications is available from sources such as the National Institute for Health and Care Excellence and the British National Formulary.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 03/09/2014 15:31:00 answering member 4020 label Biography information for George Freeman
tabling member	304 label Biography information for Mr Roger Godsiff